September 14, 2018
March 28, 2018Full List »
Dr. Richard Aplenc is a Professor of Pediatrics in the Department of Pediatrics and a core faculty member of the Center for Pediatric Clinical Effectiveness at CHOP. Dr. Aplenc’s research focuses on improving the outcomes of children with cancer, particularly acute myeloid leukemia (AML.) His work involves the treatment of AML in children and the use of genetic data to predict treatment response to therapeutic interventions. Dr. Aplenc has NIH funded research efforts in pediatric AML focused on determining the genetic predictors of treatment response (specifically relapse and infection risk) and using administrative/billing data to augment NCI funded cooperative oncology group clinical trials. He is currently leading a genome-wide genotyping effort to discover genetic variations that change the risks of relapse, life-threatening infections, and heart complications in children treated for AML. He also leads several efforts to use administrative data sets to improve the care of children with AML, particularly focusing on antibiotic and intensive care use.
Dr. Aplenc leads a large, Phase III trial for children with acute myeloid leukemia in the Children’s Oncology Group and serves as the Vice-Chair of the COG AML Committee. In addition to this work, Dr. Aplenc also leads Phase I trials for children whose cancers have not responded to standard therapy. These trials include gemtuzumab, dasatinib and obatoclax. He is the Primary Investigator at Children’s Hospital of Philadelphia for multiple Phase I trials that are offered through the Children’s Oncology Group and he helps lead the Hematologic Malignancies Program and Experimental Therapeutics Program here at CHOP.
The Children's Hospital of Philadelphia has a long tradition of embracing the total care of patients and their families. Every child receiving complex cancer therapy needs the expertise of more than one provider. That is why Dr. Aplenc works with other CHOP physicians, nurses and social workers to provide a team approach to total care. This kind of collaboration with the family and patient helps provide the best, most modern and sophisticated care — not only nationally, but in the world.